Acelyrin, Inc. (SLRN)

NASDAQ: SLRN · IEX Real-Time Price · USD
-0.15 (-0.77%)
May 26, 2023, 4:30 PM EDT - Market closed

Company Description

ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

We are driven by our sense of urgency to bring life-changing therapies to patients globally, a core value that we refer to as “courageous caring.” Our initial focus is on the treatment of diseases with pathology related to excess activation of the immune system, an area where our management and team bring industry-leading expertise.

We acquired our portfolio of product candidates with the intent to develop and commercialize novel therapies that we believe may provide the opportunity to offer clinically meaningful, differentiated benefits for patients by improving upon the efficacy and/or safety of existing therapeutics directed against established targets, such as currently marketed anti-interleukin (IL)-17A agents, or by targeting new modalities.

In each case, our strategy is to identify candidates we believe are “diamonds in the rough,” where, based on molecule characteristics, our collective experience and expertise, and the evolving scientific and medical understanding, we can establish a clinical development plan that tests our hypotheses as to what those benefits could mean for patients.

Subsequently, we plan to utilize the results from initial clinical trials and the learnings we obtain from emerging biology to potentially expand the application of our candidates to other indications in which there are significant unmet needs.

Acelyrin, Inc.
Acelyrin logo
Country United States
Founded 2020
IPO Date May 5, 2023
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Shao-Lee Lin, M.D., Ph.D.

Contact Details

4149 Liberty Canyon Road
Agoura Hills, CA 91301
United States
Phone (805) 730-0360

Stock Details

Ticker Symbol SLRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001962918
Employer ID 85-2406735
SIC Code 2834

Key Executives

Name Position
Shao-Lee Lin, M.D., Ph.D. Founder, Chief Executive Officer and Director
Mardi C. Dier Chief Financial Officer and Chief Business Officer
Melanie Gloria Chief Operating Officer
Mina Kim Chief Legal and Administrative Officer
Ron Oyston Chief People Officer
Paul M. Peloso, M.D. Chief Medical Officer
Bruce C. Cozadd Chair and Director
Dan Becker, M.D., Ph.D. Director
Alan Colowick, M.D., M.P.H. Director
Henry O. Gosebruch Director

Latest SEC Filings

Date Type Title
May 19, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
May 19, 2023 SC 13D General statement of acquisition of beneficial ownership
May 19, 2023 SC 13D General statement of acquisition of beneficial ownership
May 9, 2023 8-K Current Report
May 8, 2023 S-8 Securities to be offered to employees in employee benefit plans
May 5, 2023 424B4 Prospectus
May 4, 2023 EFFECT Notice of Effectiveness
May 4, 2023 S-1MEF Registration adding securities to prior Form S-1 registration
May 4, 2023 CERT Certification by an exchange approving securities for listing
May 3, 2023 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933